

**Publication Instructions:**  
**BMT CTN Protocol 1203**  
**- Primary and Ancillary Studies –**

---

The requirements below are for publications and presentations made pursuant to the primary BMT CTN Study 1203. **For ancillary/biologics studies, please contact the email below as there are very specific requirements from Millennium regarding use of samples.**

**Acknowledgment Requirements:**

**For all Publications, Reports, Presentations, Symposiums, etc.**

“Support for this study was provided by grant #U10HL069294 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute along with contributions by Millennium Pharmaceuticals, Inc. The content is solely the responsibility of the authors and does not necessarily represent the official views of the above mentioned parties.”

**The following language should be inserted in the acknowledgements for all BMT CTN Studies that utilize CIBMTR data:**

The CIBMTR registry is supported primarily by the U24-CA76518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases and from HHS234200637015C (HRSA/DHHS) to the Center for International Blood and Marrow Transplant Research.

**Review Requirements:**

**For all Publications, Reports, Presentations, Symposiums, etc.**

**BMT CTN:** Abstracts, presentations, and proposed publications relating to data obtained from BMT CTN protocols or to activities of BMT CTN Committees or Protocol Teams are to be submitted to the DCC for review.

**Millennium:**

The BMT CTN will provide Millennium with a draft copy of any proposed disclosure, including all publications and public presentations and/or a summary of the Data resulting from the Study when such information is ready to be made available to the public to permit Millennium time in which to prepare application(s) for letters of patent regarding any Development and to allow Millennium to review said publication for information provided by Millennium that is Confidential Information (as defined in the Memorandum of Agreement between Millennium and the BMT CTN) of Millennium. BMT CTN will provide a copy of any proposed disclosure to Millennium for review (a) in the case of a manuscript, at least thirty (30) days prior to the date of submission for publication or of public disclosure; (b) in the case of a draft abstract, at least fourteen (14) days prior to the date of submission for publication or public disclosure; (c) in the case of a final abstract, at least seven (7) days prior to

the date of submission for publication or public disclosure; or (d) in the case of a poster or oral presentation, at least seven (7) days prior to the date of submission for publication or public disclosure. If Millennium reasonably determines that such Confidential Information of Millennium is being disclosed, it will require the BMT CTN to redact the information. BMT CTN agrees to consider all comments of Millennium in good faith but in no event will BMT CTN, any Transplant Center or any Transplant Center investigator be obligated to incorporate Millennium's comments into the publication or public disclosure. Upon request by Millennium, BMT CTN will withhold such submission for publication or other public disclosure for an additional forty-five (45) days to allow Millennium to seek patent protection to the extent Millennium is entitled to seek patent protection pursuant to the Memorandum of Agreement.

**For correlative studies utilizing biospecimens obtained from the NHLBI Biologic Specimen Repository (operated by the NMDP) and/or clinical data obtained from the NHLBI Data Repository Information Coordinating Center, include the following as applicable:**

If the Research Plan involves collaboration with Study Investigators, acknowledge the source of the data by including language similar to the following either in the acknowledgement or in the text of the manuscript:

*"This manuscript was prepared using BMT CTN 1203 Research Materials obtained from the NHLBI."*

If the Research Plan does not involve collaboration with Study investigators, or if the Study has ended, use the following language:

*"This manuscript was prepared using BMT CTN 1203 Research Materials obtained from the NHLBI Biologic Specimen Repository (Operated by the NMDP) and NHLBI Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the BMT CTN 1203 or the NHLBI."*

Manuscripts and abstracts resulting from the Research Plan should not use the name of the Study in the title of the manuscript/abstract unless the title clearly denotes the source of the Research Materials as being from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center.

Questions regarding the above requirements may be directed to the Data Coordinating Center, NMDP Contracts & Procurement Department at [NMDP\\_BMTCTN\\_Pub@nmdp.org](mailto:NMDP_BMTCTN_Pub@nmdp.org).